HOME >> MEDICINE >> NEWS
AMN107 has potent activity in leukemia resistant to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center (meeting abstract #37).

At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in outcome in all three phases of chronic myeloid leukemia (CML) as well as benefit in treating a form of acute lymphocytic leukemia (ALL) that shares the same genetic abnormality as CML, the Philadelphia chromosome.

"This drug is very promising and appears at this point to offer an effective option for patients who do not achieve an optimal response to Gleevec therapy," says Hagop Kantarjian, M.D., professor and chair of the Department of Leukemia.

If additional studies continue to show such results, Kantarjian says, he believes AMN107, which is taken in pill form, "will either replace Gleevec as the standard of care in the future or will be used in combination with it."

Both CML and Philadelphia-positive ALL is caused by the swapping of genetic material in bone marrow stem cells between two chromosomes, which produces an abnormality called the Philadelphia chromosome. This new gene then produces a novel tyrosine kinase (Bcr-Abl) that signals the abnormal cell growth that leads to development of leukemia.

While both Gleevec and AMN107 shut down the activity of Bcr-Abl, laboratory experiments with AMN107 show it is up to 50 times more potent because it binds more efficiently to the enzyme than does Gleevec.

In the phase I clinical trial being reported, 119 patients who were resistant to Gleevec were given AMN107, and in some cases the dose was increased up to twelve fold. The researchers found that the range of response varied, depending on the form of the cancer and the presence of genetic mutations. For example, hematologic response fr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
10-Dec-2005


Page: 1 2

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. Electric fields have potential as a cancer treatment
3. STAMP system can help professionals to identify potentially violent individuals
4. AMPAKINE compounds a new potential treatment for respiratory depression
5. Herb shows potential to reduce cancer-related fatigue
6. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
7. Women with breast cancer do not get potentially life-saving information, survey reveals
8. Eating cured meats frequently can lead to lower lung function and potential COPD
9. Clinical studies evaluate potential treatments for mouth ulcers
10. Synthetic production of potential pharmaceuticals dramatically simplified by Scripps research team
11. Obesity and environmental chemicals -- New research probes potential link

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AMN107 has potent activity leukemia resistant Gleevec

(Date:7/24/2014)... 25, 2014 The report, “Content ... CDN market into various sub-segments with an in-depth ... the drivers and restraints for this market with ... 93 market data tables and 36 figures spread ... Delivery Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... In a July 9th article in the Money magazine ... Blossom Consulting LLC , was quoted in a Family Finance ... the High Cost of Infertility . Her advice began with, ... your chance of success from the first attempt.” The article ... “I am always happy to talk with the media about ...
(Date:7/24/2014)... Kathleen Doheny HealthDay Reporter ... of obese children often don,t view their kids as unhealthy ... according to a new study. The children of the ... clinic at the Hasbro Children,s Hospital in Providence, R.I. ... good," said study researcher Dr. Kyung Rhee, now an assistant ...
(Date:7/24/2014)... and obese preschoolers works better when treatment targets both ... is targeted, according to research published this week in ... Buffalo and Women and Children,s Hospital of Buffalo., Children ... had one parent who participated in the study who ... index (BMI) measurements, calculated based on height and weight., ...
(Date:7/24/2014)... material like a medical device or surgical implant is ... According to Northwestern University,s Guillermo Ameer, most of the ... device,s function. , "You will always get an inflammatory ... engineering in Northwestern,s McCormick School of Engineering and Applied ... of Medicine. "A problem with commonly used plastic materials, ...
Breaking Medicine News(10 mins):Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2
(Date:7/24/2014)... SOUTH PLAINFIELD, N.J. , July 24, 2014 /PRNewswire/ ... announced that the Company will host a webcast conference ... and provide an update on the company,s business and ... (ET) before the opening of the market. ... 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
Cached News: